Spinal cord injury is typically a devastating injury with no or only limited neurologic recovery. Recent papers have reported enhancement of neurologic recovery following spinal cord injury with both methylprednisolone and GM-1 ganglioside. This paper provides additional details of the GM-1 study and a further analysis of recovery of motor function for each of the ten neurologic levels assessed in the study. This additional analysis provides further evidence that the largest enhanced recovery of motor function in the GM-1 treatment group occurred in the muscles of the lower extremities and is consistent with the enhanced recovery occurring in the white matter tracts passing through the level of injury.
Get full access to this article
View all access options for this article.
References
1.
AMERICAN SPINAL INJURY ASSOCIATION. (1984). Standards for Neurological Classification of Spinal Injury Patients. American Spinal Injury Association: Chicago (IL).
2.
ANDOS. (1983). Review: gangliosides in the nervous system. Neurochem. Int.5, 507–537.
3.
ARGENTINOC., SACCHETTIM., TONID., et al. (1989). GM1 ganglioside therapy in acute ischemic stroke. Stroke20, 1143–1149.
4.
BATTISTINL., CESARIA., GALLIGIONIF., et al. (1985). Effects of GM-1 ganglioside in cerebrovascular diseases: A double-blinded trial in 40 cases. Eur. Neurol.24, 343–351.
5.
BEATTIEM.S., STOKESB.T., and BRESNAHANJ.C. (1988). Experimental spinal cord injury. Strategies for acute and chronic intervention based on anatomic, physiological, and behavioral studies. In: Pharmacologial Approaches to the Treatment of Brain and Spinal Cord Injury. SteinD.G., and SabelB.A. (eds). Plenum: New York, pp. 43–74.
6.
BLIGHTA.R., and YOUNGW. (1989). Central axons in injured cat spinal cord recover electro-physiological function following remyelination by Schwann cells. J. Neurol. Sci.91(1-2), 15–34.
7.
BRACKENM.B., FREEMAND.H., and HELLENBRANDK. (1981). Incidence of acute traumatic hospitalized spinal cord injury in the United States. Am. J. Epidemiol.113, 615–622.
8.
BRACKENM.B., SHEPARDM.J., COLLINSW.F., et al. (1990). A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N. Engl. J. Med.322(20), 1405–1411.
9.
CECCARELLIB., APORTIF., and FINESSOM. (1976). Effects of brain gangliosides in functional recovery in experimental regeneration and reinnervation. In: Advances in Experimental Medicine and Biology, vol. 71. PorcellatiG., CeccarelliB., and TettamantiG. (eds). Plenum: New York, pp. 275–293.
10.
COMMISSIONGJ.W., and TOFFANOG. (1986). The effect of GM1 ganglioside on coerulospinal, noradrenergic, adult neurons and on fetal monoaminergic neurons transplanted into the transected spinal cord of the adult rat. Brain Res.380(2), 205–215.
11.
CUELLOA., STEPHENSP., TAGARIP., SOFRONIEWM., and PEARSONR. (1986). Retrograde changes in the nucleus basalis of the rat are prevented by exogenous ganglioside GM1. Brain Res.376, 373–377.
12.
DI GREGORIOF., FERRARIG., MARINIP., SILIPOANDIR., and GORIOA. (1984). The influence of gangliosides on neurite growth and regeneration. Neuropediatrics Suppl93, 6.
13.
DUCKERT.B., SALCMANM., and DANIELLH.B. (1978). Experimental cord trauma. III. Therapeutic effect of immobilization and pharmacologic agents. Surg. Neurol.10, 71–76.
14.
FADENA.I. (1987a). Pharmacotherapy in spinal cord injury: A critical review of recent development. Clin. Neuropharmacol.10(3), 193–204.
15.
FADENA.I. (1987b). Opiate-receptor antagonists, thyrotropin-releasing hormone (TRH), and TRH analogs in the treatment of spinal cord injury. Cent. Nerv. Syst. Trauma4(4), 217–226.
16.
FADENA.I. (1988). Role of thyrotropin-releasing hormone and opiate receptor antagonists in limiting central nervous system injury. Adv. Neurol.47, 531–546.
17.
FEHLINGSM.G. (1989). Blood flow, Ca channel blockers, and neural mechanisms of spinal cord injury. J. Neurotrauma6, 49.
18.
FRANKELH.L., HANCOCKD.O., HYSLOPG., et al. (1969). The value of postural reduction in the initial management of closed injuries to the spine with paraplegia and tetraplegia. Paraplegia7, 179–192.
GEISLERF.H. (1986). Central nervous system injuries. In: Shock Trauma/Critical Care Handbook. DunhamC.M., and CowleyR.A. (eds). Aspen Publishers: Rockville (MD), pp. 313–353.
21.
GEISLERF.H. [Comment following] HOLTZA., NYSTRÖMB., and GERDINB. (1990). Relation between spinal cord blood flow and functional recovery after blocking weight-induced spinal cord injury in rats. Neurosurgery26(6), 952–957.
22.
GEISLERF.H., DORSEYF.C., and COLEMANW.P. (1991). Recovery of motor function after spinal-cord injury-a randomized, placebo-controlled trial with GM-1 ganglioside. N. Engl. J. Med.324(26), 1829–1838.
23.
GORIOA. (1986). Ganglioside enhancement of neuronal differentiation, plasticity, and repair. CRC Crit. Rev. Clin. Neurobiol.2, 241–296.
24.
GORIOA. (1988). Gangliosides as a possible treatment affecting neuronal repair processes. In: Advances in Neurology: Functional Recovery in Neurological Disease, vol 47. WaxmanS.G. (ed.). Raven Press: New York, pp. 523–530.
25.
GORIOA., FERRARIG., FUSCOM., JANIGROD., ZANONIR., and JONSSONG. (1984a). Gangliosides and their effects on rearranging peripheral and central neural pathways. Cent. Nerv. Syst. Trauma1, 29–37.
26.
GORIOA., APORTIF., DI GREGORIOF., SCHIAVINATOA., SILIPRANDIR., and VITADELLOM. (1984b). Ganglioside treatment of genetic and alloxan-induced diabetic neuropathy. Adv. Exp. Med. Biol.174, 549–564.
27.
GORIOA., DI GIULLOA.M., YOUNGW., et al. (1986). GM1 effects on chemical, traumatic and peripheral nerve induce lesions to the spinal cord. In: Proceedings of the Meeting Development and Plasticity of the Mammalian Spinal Cord, vol III. GoldbergerM.E., GorioA., and MurrayM. (eds.). Liviana Press.
28.
HADJICONSTANTINOUM., and NEFFN.H. (1986). Treatment with GM1 ganglioside increases rat spinal cord indole content. Brain Res.366(1-2), 343–345.
29.
HADJICONSTANTINOUM., and NEFFN.H. (1988). Treatment with GM1 ganglioside restores striatal dopamine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse. J. Neurochem.51(4), 1190–1196.
30.
HADJICONSTANTINOUM., MARIANIA.P., and NEFFN.H. (1989). GMI ganglioside-induced recovery of nigrostriatal dopamin-ergic neurons after MPTP: An immunohistochemical study. Brain Res.484(1-2), 297–303.
31.
HOLTZA., NYSTRÖMB., and GERDINB. (1990). Relation between spinal cord blood flow and functional recovery after blocking weight-induced spinal cord injury in rats. Neurosurgery26(6), 952–957.
32.
IOSAD., MASSARID.C., and DORSEYF.C. (1991). Chagas' cardioneuropathy: Effect of ganglioside treatment in chronic dysautonomic patients-a randomized, double-blind, parallel, placebo-controlled study. Am. Heart. J.122, 775–785.
33.
JANSSENL. and HANSEBOUTR.R. (1989). Pathogenesis of spinal cord injury and newer treatments. A review. Spine14(1), 23–32.
34.
JONSSONG., GORIOA., HALLMANH., JANIGROD., KO-JIMAH., and LUTHMANJ. (1986). GM1 ganglioside treatment enhance regrowth of central and peripheral noradrenaline neurons after selection 6-hydroxydopamine-induced lesions. In: Processes of Recovery from Neural Trauma. GiladG.M., GorioA., and KreutzbergG.W. (eds.). Springer-Verlag: Berlin/Heidelberg, 1986.
35.
KALSBEEKW.D., MCLAURINR.L., HARRISB.S.H., and MILLERJ.D. (1980). The national head and spinal cord injury survey: major findings. J. Neurosurg.53, S19–S32.
36.
KRAUSJ.F., FRANTIC.E., RIGGINSR.S., RICHARDSD., and BORHANIN.O. (1975). Incidence of traumatic spinal cord lesions. J. Chron. Dis.7, 471–492.
37.
LEDEENR.W. (1978). Ganglioside structures and distribution: Are they localized at the nerve ending. J. Supramol. Struct. Cell Biochem.8, 1–7.
38.
LEDEENR.W. (1984). Introductory review, biology of gangliosides: Neurotogenic and neuronotrophic properties. J. Neurosci. Res.12, 147–159.
39.
MERRIAMW.F., TAYLORT.K.F., RUFFS.J., and MCPHAILM.J. (1986). A reappraisal of acute traumatic central cord syndrome. J. Bone Joint Surg.68B(5), 708–713.
40.
PAPOI., BENEDITTIA., CARTERIA., MERLIG.A., MIN-GRINOS., and BRUNOR. (1991). Monosialoganglioside in subarachnoid hemorrhage. Stroke22, 22–26.
41.
ROSNERM.J. [correspondence] and BRACKENM.B. [reply] (1991). National Acute Spinal Cord Injury Study of methylprednisone or naloxone. Neurosurgery28(4), 628–629.
42.
SABELB.A. (1988). Anatomic mechanisms whereby gangliosides induce brain repair: What do we really know. In: Pharmacological Treatment of Brain and Spinal Cord Injury. SteinD.G., and SabelB.A. (eds.). Plenum: New York, pp. 94–113.
43.
SABELB.A., and SCHNEIDERG.E. (1988). Enhanced sprouting of retinotectal fibers after early superior colliculus lesions in hamsters treated with gangliosides. Exp. Brain Res.71, 365–376.
44.
SABELB.A., and STEIND.G. (1986). Pharmacological treatment of central nervous system injury. Nature323, 493.
45.
SABELB.A., SLAVINM.D., and STEIND.G. (1984a). GM-1 ganglioside treatment facilitates behavioral recovery from bilateral brain damage. Science225, 340–342.
46.
SABELB.A., DUNBARG.L., and STEIND.G. (1984b). Gangliosides minimize behavioral deficits and enhance structural repair after brain injury. J. Neurosci. Res.12, 429–443.
47.
SABELB.A., DUNBARG.L., BUTLERW.M., and STEIND.G. (1985). Gangliosides, neuroplasticity and behavioural recovery after brain damage. In: Brain Plasticity Learning and Memory. WillB.E., SchmittP., and Dairymple-AlfordJ.C. (eds.). Plenum: New York, pp. 481–493.
48.
SABELB.A., DEL MASTROR., DUNBARG.L., and STEIND.G. (1987). Reduction of anterograde degeneration in brain damaged rats by GM-1 gangliosides. Neurosci. Res.77, 360–366.
49.
SABELB.A., GOTTLIEBJ., and SCHNEIDERG.E. (1988). Exogenous GM1 gangliosides protect against retrograde degeneration following posterior neocortex lesions in developing hamsters. Brain Res.459, 373–380.
50.
SAULT.G., and DUCKERT.B. (1982). Treatment of spinal cord injury. In: Pathophysiology of Shock, Anoxia, and Ischemia. CowleyR.A., and TrumpB.E. (eds.). Waverly Press: Baltimore (MD), pp. 624–640.
51.
SIEGELJ.H., and DUNHAMC.M. (1987). Trauma, the disease of the 20th century. In: Trauma Emergency Surgery and Critical Care. Churchill Livingstone: New York, pp. 1–32.
52.
SOFRONIEWM.V., PEARSONR.C.A., CUELLOA.C., TAGARIP.C., and STEPHENSP.H. (1986). Parenterally administered GM-1 ganglioside prevents retrograde degeneration of the rat basal forebrain. Brain Res.398, 393–396.
53.
STOVERS.L., and FINEP.R. (eds.). (1986). Spinal Cord Injury: The Facts and Figures. University of Alabama at Birmingham: Birmingham (AL).
54.
TOFFANOS., SAVOINIG., MARONIF., LOMBARDIM.G., CALZAL., AGNATIL.F. (1983). GM-1 ganglioside stimulates the regeneration of dopaminergic neurons in the central nervous system. Brain Res.261, 163–166.
55.
TOFFANOG., SAVOINIG.E., MORONIF., LOMBARDIM.G., CALZAL., and AGNATIL.F. (1984). Chronic GM-1 ganglioside treatment reduces dopamine cell body degeneration in the substantia nigra after unilateral hemitransection in rat. Brain Res.296, 233–239.
URBANICSR., GREENBERGJ.H., TOFFANOG., and REIVICHM. (1989). Effect of GM1 ganglioside after focal cerebral ischemia in halothane-anesthetized cats. Stroke20, 795–802.
58.
WALKERM.D. (1991). Acute spinal-cord injury [editorial; comment]. N. Engl. J. Med.324(26), 1885–1887.
59.
WOJCIKM., VLASJ., and ODERELT-NOWAKB. (1982). The stimulating effect of ganglioside injection on the recovery of choline acetyltransferase activities in the hippocampus of the rat after septal lesions. Neuroscience7, 495–500.
60.
YOUNGW. (1986). Ca paradox in neural injury: A hypothesis. Cent. Nerv. Syst. Trauma3(3), 235–251.
61.
YOUNGW. (1987). Cellular defenses against excessive calcium entry in trauma ischemia. In: Critical Care State of the Art. CerraF.B., and ShoemakerW.C. (eds.). The Society of Critical Care Medicine: Fullerton (CA), pp. 71–98.
62.
YOUNGW. (1989). Recovery mechanisms in spinal cord injury: Implications for regenerative therapy. In: Neural Regeneration and Transplantation, Frontier of Clinical Neuroscience, vol. 6. SeilF.J. (ed.). Alan R. Liss: New York, pp. 157–169.
63.
YOUNGH.F., and BECKERD.P. (1982). Spinal cord injury. In: Pathophysiology of Shock, Anoxia, and Ischemia. CowleyR.A., and TrumpB.E. (eds.). Waverly Press: Baltimore (MD), pp. 613–624.
64.
YOUNGW., and SAKATANIK. (1990). Neurophysiologic mechanisms of somatosensory evoked potential changes. In: Preventing Intraoperative Neural Injury. SalzanS. (ed.). Humana Press: Clifton (NJ).
